Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $123.33 Consensus Price Target from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has earned a consensus recommendation of “Hold” from the twenty brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $123.33.

A number of equities analysts recently commented on ZBH shares. BTIG Research lowered their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Royal Bank of Canada raised their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Wells Fargo & Company upped their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Evercore ISI decreased their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Finally, Canaccord Genuity Group cut their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th.

Zimmer Biomet Trading Down 0.3 %

NYSE ZBH opened at $103.22 on Friday. Zimmer Biomet has a 12 month low of $101.47 and a 12 month high of $133.90. The stock has a market capitalization of $20.55 billion, a P/E ratio of 19.62, a PEG ratio of 1.96 and a beta of 1.02. The firm’s 50-day moving average is $108.36 and its two-hundred day moving average is $108.14. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter last year, the company posted $1.65 EPS. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. On average, sell-side analysts anticipate that Zimmer Biomet will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.93%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. grew its position in shares of Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after acquiring an additional 722,041 shares during the last quarter. Geode Capital Management LLC grew its position in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares during the last quarter. Van ECK Associates Corp increased its stake in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after purchasing an additional 411,163 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Zimmer Biomet by 0.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider’s stock valued at $277,357,000 after buying an additional 9,990 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Zimmer Biomet by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,810,770 shares of the medical equipment provider’s stock worth $196,523,000 after buying an additional 154,447 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.